Attovia Therapeutics is a four-business-day-old public company with a single Phase 1 asset, a platform that has produced two IND-stage follow-ons, and a post-IPO cash pile that management believes funds the enterprise into 2029. Shares began trading on the Nasdaq Global Market on August 6, 2026 at an initial public offering price of $17.00, the offering was led by Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets with LifeSci Capital also in the syndicate, and the stock closed its first session at $21.90 and traded as high as $24.32 and as low as $16.15 across the eleven trading sessions observed through the report date, with the most recent close at $22.28. The thesis here is asymmetric in a small-cap way: the equity carries a market capitalization in the high nine figures against a stated cash position of roughly $115.1 million at June 30, 2026, which the IPO net proceeds of approximately $265.1 million expand to a pro-forma cash position of close to $380 million. Capital is therefore not the binding constraint, clinical execution is. The investment case rests on whether the company can convert initial Phase 1 data on its lead anti-IL-31 candidate, ATTO-1310, into a clean Phase 2 readout in chronic pruritic diseases while keeping the bispecific ATTO-2306 and the trispecific ATTO-1091 on their stated timelines into the clinic in the first half of 2027. The setup favors investors who can underwrite a binary biotech with platform optionality, a long runway, and management whose collective track record is concentrated in early-stage discovery rather than late-stage commercial launches. The most important data points, all taken from the final prospectus dated August 4, 2026 and the related 8-K filed August 6, 2026, are a 2025 net loss of $60.6 million against no recurring product revenue, first-quarter 2026 net loss of $18.7 million, a cumulative $255.8 million of equity raised since inception, and a stated runway extending into 2029. Readers should treat this as a high-risk, high-optionality position in which the platform narrative, the recent capital raise, and the early clinical signals matter more than the P&L, which is structurally loss-making for several years. The next twelve months carry three named inflection events: an interim Phase 1b update on ATTO-1310, the start of a Phase 2 trial in chronic pruritus of unknown origin or high-itch atopic dermatitis, and IND clearance for the two earlier-stage candidates.